Pharmacoeconomic review report. Letermovir (Prevymis) (Merck Canada Inc.).
Letermovir is an antiviral agent that can be administered orally or intravenously at a dosage of 480 mg daily (or 240 mg daily if co-administered with cyclosporine A) in patients undergoing an allogeneic hematopoietic stem cell transplant (HSCT) as prophylaxis of cytomegalovirus (CMV) infection. The...
Saved in:
| Online Access: |
Full text |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Ottawa (ON) :
CADTH,
2018
|
| Edition: | Final pharmacoeconomic review report (with redactions). |
| Series: | Common drug review clinical review report.
|
| Subjects: |
